IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Harrell Investment Partners LLC

Harrell Investment Partners LLC boosted its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,779 shares of the medical research company’s stock after buying an additional 560 shares during the period. Harrell Investment Partners LLC’s holdings in IQVIA were worth $3,028,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IQV. 1832 Asset Management L.P. increased its stake in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after acquiring an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new position in IQVIA during the 2nd quarter worth approximately $70,610,000. Impax Asset Management Group plc boosted its stake in shares of IQVIA by 19.3% in the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after buying an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board boosted its stake in shares of IQVIA by 6.6% in the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after buying an additional 211,653 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. raised its position in IQVIA by 285.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after acquiring an additional 198,808 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on IQV shares. Barclays upped their price target on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 23rd. Royal Bank of Canada initiated coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target on the stock. UBS Group raised their price objective on IQVIA from $295.00 to $300.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Robert W. Baird lifted their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research note on Friday, September 20th. Five investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $268.36.

IQVIA Trading Up 0.8 %

Shares of NYSE:IQV traded up $1.82 during trading on Monday, reaching $231.08. The stock had a trading volume of 107,577 shares, compared to its average volume of 1,066,294. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. The stock has a market cap of $42.10 billion, a P/E ratio of 31.36, a PEG ratio of 2.18 and a beta of 1.49. The business has a fifty day moving average price of $239.16 and a 200-day moving average price of $231.59. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.22 EPS. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.